The Mesoblast Limited (ASX: MSB) share price has been regaining some of its recent losses today.
In afternoon trade, shares in the regenerative medicines company are fetching $1.20, up 16.5%. Despite the gain, shareholders are still a distant 52% below Mesoblast’s 52-week high of $2.52.
Could the shorts be covering?
While the market is throwing support behind the Mesoblast share price today, the shifting sentiment is not a result of a positive announcement.
In fact, the ASX-listed drug developer hasn’t released any news since 25 February. Aside from that release, the only other news to arise is the company’s removal from the S&P/ASX 200 Index (ASX: XJO) — which was revealed on Friday.
However, thanks to my Foolish colleague, James, we know that Mesoblast made the top 10 most shorted ASX shares last week. From the ASIC data, the recent weakness in the Mesoblast share price coincided with a 9.8% short interest last week.
This might suggest shorters might be taking some of their profits off the table today after a prolonged downward run in Mesoblast shares.
Between 11 December 2020 and today, the unprofitable biotech has suffered a 74% fall in its share price. Given this, the far majority of short-sellers were likely in profit leading up to today.
How does the Mesoblast share price compare to its peers?
Looking at the company on a year-to-date (YTD) basis, the performance of the Mesoblast share price is roughly in line, if not better in some cases, than its ASX-listed pharmaceutical peers.
Since the year kicked off, Mesoblast shares have fallen 15.2%. For comparison, let’s look at the performance of other similar companies.
- CSL Limited (ASX: CSL) down 13% YTD
- Telix Pharmaceuticals Ltd (ASX: TLX) down 40.8% YTD
- Mayne Pharma Group Ltd (ASX: MYX) down 32.3% YTD
Finally, based on the current Mesoblast share price, the company holds a market capitalisation of $772 million.
The post Mesoblast (ASX:MSB) share price rebounds 15%, what’s been happening? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Mesoblast right now?
Before you consider Mesoblast, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Mesoblast wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- These are the 10 most shorted ASX shares
- These ASX 200 shares are being dumped out of the index and replaced with…
- 5 things to watch on the ASX 200 on Monday
- These are the 10 most shorted ASX shares
- These are the 10 most shorted ASX shares
Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/qlHGiXa
Leave a Reply